휴온스
Financials
Valuation Metrics
휴온스's Market Cap is ₩2053B. At end of 2025 it was ₩3282B. Ranked #791 of 2,410 in KR market (top 33%), #353 of 1,631 on KOSDAQ (top 22%), #86 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 205.33B KRW | KR#791/2,410 Sec#86/231 |
| Revenue | 607.75B KRW | KR#553/2,410 Sec#24/231 |
| Net Income | 17.16B KRW | KR#768/2,410 Sec#52/231 |
| Total Assets | 650.03B KRW | KR#649/2,410 Sec#36/231 |
| Net Assets | 405.13B KRW | KR#591/2,410 Sec#36/231 |
| Employees | 1,049 | KR#245/2,410 Sec#17/231 |
| Value | ||
| P/E | 11.97x | KR#979/2,410 Sec#54/231 |
| P/B | 0.51x | KR#888/2,410 Sec#45/231 |
| PEG | 0.16x | KR#526/2,410 Sec#31/231 |
| P/S | 0.34x | KR#708/2,410 Sec#19/231 |
| EV/EBITDA | 14.27x | KR#875/2,410 Sec#50/231 |
| FCF Yield | 12.15% | KR#562/2,410 Sec#18/231 |
| Profitability | ||
| ROE | 4.24% | KR#1,189/2,410 Sec#83/231 |
| ROA | 2.64% | KR#1,099/2,410 Sec#82/231 |
| Op. Margin | 3.62% | KR#1,147/2,410 Sec#84/231 |
| Revenue Growth | 2.08% | KR#1,375/2,410 Sec#136/231 |
| Earnings Growth | 75.68% | KR#451/2,410 Sec#31/231 |
| Financial Health | ||
| Debt Ratio | 60.45% | KR#1,096/2,410 Sec#129/231 |
| Total Debt | 157.79B KRW | KR#590/2,410 Sec#31/231 |
| FCF | 24.95B KRW | KR#458/2,410 Sec#27/231 |
| Cash | 49.50B KRW | KR#742/2,410 Sec#43/231 |
| Current Ratio | 1.41x | KR#1,270/2,410 Sec#136/231 |
| Net Debt/EBITDA | 4.93x | KR#1,024/2,410 Sec#77/231 |
| Dividend | ||
| Div. Yield | 5.43% | KR#277/2,410 Sec#7/231 |
| Div. Growth | 46.03% | KR#268/2,410 Sec#10/231 |
| Performance | ||
| 1Y Return | -41.30% | KR#1,764/2,410 Sec#149/231 |
| 1M Return | -12.01% | KR#1,367/2,410 Sec#138/231 |
| From 52W High | -58.70% | KR#1,599/2,410 Sec#132/231 |
| 1Y MDD | -55.89% | KR#1,217/2,410 Sec#100/231 |
| Trading | ||
| Volume | 10,089 shares | KR#1,547/2,410 Sec#161/231 |
| Trading Value | 172.1M KRW | KR#974/2,410 Sec#108/231 |
| Foreign Own. | 16.06% | KR#294/2,410 Sec#17/231 |
| Per Share | ||
| EPS | 1,432 KRW | KR#583/2,410 Sec#40/231 |
| BPS | 33,819 KRW | KR#341/2,410 Sec#22/231 |
Company Info
Founded in 1965, the company re-listed on KOSDAQ in 2016 following a spin-off from Huons Global. It holds stakes in Huons N (health functional food company), Huons BioScience (pharmaceutical manufacturing), and PanGen (biosimilar EPO producer), which are slated for subsidiary incorporation in 2025. The professional pharmaceutical business supplies various professional pharmaceuticals domestically, while its beauty and well-being business expands into well-being pharmaceuticals, obesity treatments, medical devices, and health functional foods. Huons was established in 2016 and is headquartered in Seongnam-si, Gyeonggi-do.